The Europe RNA Analysis Market is expected to witness market growth of 15.1% CAGR during the forecast period (2022-2028).
Long noncoding RNAs are a prominent subclass of ncRNAs. During the extensive sequencing of cDNA libraries, lncRNAs were first identified as a functional class and first reported in mice. LncRNAs have been implicated in a wide range of molecular processes, including chromatin remodeling, transcriptional regulation, and posttranscriptional processing, albeit the bulk of these is still poorly understood.
Analysis of RNA transcripts using next-generation sequencing techniques, which need RNA to be translated into complementary DNA before sequencing, is known as RNA. It uses a variety of methods, including q PCR and microarrays. The most popular method utilized in research labs is microarray technology. It is called quantitative reverse transcription (q PCR) and is carried out using the polymerase chain reaction. Q PCR is used to identify the presence and quantity of RNA by converting it into cDNA.
The health technology sector can be led by the United Kingdom. They already have some of the most successful health technology companies in the world, which contribute to innovative innovations and improve the country's reputation abroad as a strong scientific and research base. Additionally, it has the potential to create an ecosystem that consistently generates the best transferable health-tech as well as cutting-edge approaches and insights that can enhance health outcomes.
The Germany market dominated the Europe RNA Analysis Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $1,863.5 million by 2028. The UK market is experiencing a CAGR of 14.1% during (2022 - 2028). Additionally, The France market is expected to exhibit a CAGR of 16% during (2022 - 2028).
Based on Product, the market is segmented into Kits & Reagents, Instruments and Services. Based on Technology, the market is segmented into Real Time-PCR (qPCR) Technology, Sequencing Technology, Microarray Technology and Others. Based on End-use, the market is segmented into Government Institutes & Academic Centers, Hospitals & Clinics, Pharmaceutical & Biotechnology Companies and Contract Research Organizations (CROs). Based on Application, the market is segmented into Infectious Diseases & Pathogenesis, Epigenetics, RNA Structure & Molecular Dynamics, Development & Delivery of RNA Therapeutics, Construction of RNA Expression Atlas, Alternative RNA Splicing and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include F. Hoffmann-La Roche Ltd., Danaher Corporation, Agilent Technologies, Inc., Thermo Fisher Scientific, Inc., Qiagen N.V., Illumina, Inc., Bio-Rad Laboratories, Inc., Eurofins Scientific Group, Merck Group, and Promega Corporation.
Long noncoding RNAs are a prominent subclass of ncRNAs. During the extensive sequencing of cDNA libraries, lncRNAs were first identified as a functional class and first reported in mice. LncRNAs have been implicated in a wide range of molecular processes, including chromatin remodeling, transcriptional regulation, and posttranscriptional processing, albeit the bulk of these is still poorly understood.
Analysis of RNA transcripts using next-generation sequencing techniques, which need RNA to be translated into complementary DNA before sequencing, is known as RNA. It uses a variety of methods, including q PCR and microarrays. The most popular method utilized in research labs is microarray technology. It is called quantitative reverse transcription (q PCR) and is carried out using the polymerase chain reaction. Q PCR is used to identify the presence and quantity of RNA by converting it into cDNA.
The health technology sector can be led by the United Kingdom. They already have some of the most successful health technology companies in the world, which contribute to innovative innovations and improve the country's reputation abroad as a strong scientific and research base. Additionally, it has the potential to create an ecosystem that consistently generates the best transferable health-tech as well as cutting-edge approaches and insights that can enhance health outcomes.
The Germany market dominated the Europe RNA Analysis Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $1,863.5 million by 2028. The UK market is experiencing a CAGR of 14.1% during (2022 - 2028). Additionally, The France market is expected to exhibit a CAGR of 16% during (2022 - 2028).
Based on Product, the market is segmented into Kits & Reagents, Instruments and Services. Based on Technology, the market is segmented into Real Time-PCR (qPCR) Technology, Sequencing Technology, Microarray Technology and Others. Based on End-use, the market is segmented into Government Institutes & Academic Centers, Hospitals & Clinics, Pharmaceutical & Biotechnology Companies and Contract Research Organizations (CROs). Based on Application, the market is segmented into Infectious Diseases & Pathogenesis, Epigenetics, RNA Structure & Molecular Dynamics, Development & Delivery of RNA Therapeutics, Construction of RNA Expression Atlas, Alternative RNA Splicing and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include F. Hoffmann-La Roche Ltd., Danaher Corporation, Agilent Technologies, Inc., Thermo Fisher Scientific, Inc., Qiagen N.V., Illumina, Inc., Bio-Rad Laboratories, Inc., Eurofins Scientific Group, Merck Group, and Promega Corporation.
Scope of the Study
Market Segments Covered in the Report:
By Product- Kits & Reagents
- Instruments
- Services
- Real Time-PCR (qPCR) Technology
- Sequencing Technology
- Microarray Technology
- Others
- Government Institutes & Academic Centers
- Hospitals & Clinics
- Pharmaceutical & Biotechnology Companies
- Contract Research Organizations (CROs)
- Infectious Diseases & Pathogenesis
- Epigenetics
- RNA Structure & Molecular Dynamics
- Development & Delivery of RNA Therapeutics
- Construction of RNA Expression Atlas
- Alternative RNA Splicing
- Others
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- F. Hoffmann-La Roche Ltd.
- Danaher Corporation
- Agilent Technologies, Inc.
- Thermo Fisher Scientific, Inc.
- Qiagen N.V.
- Illumina, Inc.
- Bio-Rad Laboratories, Inc.
- Eurofins Scientific Group
- Merck Group
- Promega Corporation
Unique Offerings from the Publisher
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Competition Analysis - Global
Chapter 4. Europe RNA Analysis Market by Product
Chapter 5. Europe RNA Analysis Market by Technology
Chapter 6. Europe RNA Analysis Market by End-use
Chapter 7. Europe RNA Analysis Market by Application
Chapter 8. Europe RNA Analysis Market by Country
Chapter 9. Company Profiles
Companies Mentioned
- F. Hoffmann-La Roche Ltd.
- Danaher Corporation
- Agilent Technologies, Inc.
- Thermo Fisher Scientific, Inc.
- Qiagen N.V.
- Illumina, Inc.
- Bio-Rad Laboratories, Inc.
- Eurofins Scientific Group
- Merck Group
- Promega Corporation
Methodology
LOADING...
